Biomarkers for immunotherapy in bladder cancer: a moving target
Abstract Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting th...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2017-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-017-0299-1 |